Novo Nordisk has officially filed #CagriSema its once-weekly injectable #amylin + #GLP-1 #combinationfor FDA approval, intensifying its head-to-head battle with Eli Lilly in a market already valued at ~$27B and still expanding fast
Host extracellular vesicles confer cytosolic access to systemic LPS licensing non-canonical inflammasome sensing and pyroptosis
Many people think that the medication does all the hard work: they inject it, their appetite drops , and they lose weight
BPI Labs uses robotic filling systems that reduce contamination risk, which is a positive factor
Most research has focused on L-arginine, with varying results depending on study design, dosage, duration, and patient population
You might be curious about how this wonder drug interacts with your body to help you shed the pounds